YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
The non-muscle invasive bladder cancer market is witnessing significant growth due to the rising global incidence of bladder cancer, advancements in immunotherapy, targeted treatments, and launch of novel therapies such as CG0070 (cretosti…
What happened According to an SEC filing dated May 15, 2026, Velan Capital Investment Management LP sold 140,000 shares of Mineralys Therapeutics in the first quarter. The estimated value of the trade was $4.11 million, based on the quarte…
Key Points Reduced stake by 140,000 shares; estimated transaction value of $4.11 million based on quarterly average price Quarter-end position value fell by $5.18 million, reflecting both trading and stock price changes Post-trade holding:…
TARA-002 demonstrates 72% complete response rate at any time, 67% complete response rate at the 6-month landmark and 55% complete response rate at the 12-month landmark in BCG-Naïve patients Favorable safety and tolerability profile with n…
* Protara Therapeutics press release [https://seekingalpha.com/pr/20430631-protara-therapeutics-announces-fourth-quarter-and-full-year-2025-financial-results-and] (TARA [https://seekingalpha.com/symbol/TARA]): Q4 GAAP EPS of -$0.37. * As o…
Favorable safety and tolerability profile with no Grade 3 or greater treatment-related adverse events Company expects to complete enrollment of the BCG-Unresponsive cohort of the ADVANCED-2 trial in 2H 2026 Company to host conference call…
NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc.(Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will particip…
(RTTNews) - The biotech industry witnessed several key clinical trial data readouts across multiple therapeutic areas, including lung cancer, cardiovascular risk, Alzheimer's, and hepatitis. - ScinoPharm secures FDA nod for Glatiramer Acet…
Protara Therapeutics NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc.(Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that man…
NEW YORK, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the closing of i…
(RTTNews) - Shares of Protara Therapeutics Inc. (TARA) dropped about 16% in pre-market trading on Friday after the company announced the pricing of its underwritten public offering of about 13.04 million shares of common stock at $5.75 per…
* Protara Therapeutics (TARA [https://seekingalpha.com/symbol/TARA]) priced [https://seekingalpha.com/pr/20330040-protara-announces-pricing-of-75-million-public-offering] its underwritten public offering of ~13.04M shares at a price to the…
NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the pricing of i…
* Protara Therapeutics (TARA [https://seekingalpha.com/symbol/TARA]) on Thursday said it has commenced an underwritten public offering of $75 million in aggregate of shares of its common stock or, in lieu of issuing common stock to certain…
NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it has comm…
(RTTNews) - Protara Therapeutics, Inc. (TARA), a clinical-stage company, is scheduled to host a conference call and live webcast to review new interim data from its phase 2 ADVANCED-2 trial on December 3, 2025. ADVANCED-2 is a phase 2 tria…
(RTTNews) - Several biotechnology and pharmaceutical companies posted notable gains in after-hours trading on Monday, following a mix of corporate updates and upcoming event announcements. Jasper Therapeutics, Inc. (JSPR) surged 21.51% to…
[Anatomy of Lymph Nodes and Lymph Flow] Jitendra Jadhav/iStock via Getty Images Protara Therapeutics (TARA [https://seekingalpha.com/symbol/TARA]) slipped ~6% in the premarket on Wednesday after posting interim data from a mid-stage trial…
NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced it will host a conference ca…
(RTTNews) - Protara Therapeutics Inc. (TARA) is scheduled to present new interim data from Cohort A of its ongoing Phase 2 trial assessing investigational cell-based therapy, TARA-002, in patients with Non-Muscle Invasive Bladder Cancer at…
* Protara Therapeutics press release [https://seekingalpha.com/pr/20300363-protara-therapeutics-announces-third-quarter-2025-financial-results-and-provides-business] (TARA [https://seekingalpha.com/symbol/TARA]): Q3 GAAP EPS of -$0.31 beat…
NEW YORK, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara” or the “Company”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced…
The stock market’s largest players – companies like Nvidia and its trillion-dollar peers – often dominate the headlines and attract most of the capital. Yet, some of the most compelling opportunities can be found at the smaller end of the…
NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara” or the “Company”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announce…
* Protara Therapeutics press release [https://seekingalpha.com/pr/20195899-protara-therapeutics-announces-second-quarter-2025-financial-results-and-provides-business] (NASDAQ:TARA [https://seekingalpha.com/symbol/TARA]): Q2 GAAP EPS of -$0…
NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara” or the “Company”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced…
NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara” or the “Company”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced…
* Protara Therapeutics (NASDAQ:TARA [https://seekingalpha.com/symbol/TARA]) has been added as a member of the broad-market Russell 3000 Index as part of the annual reconstitution, effective at the open of U.S. equity markets on Monday. * T…
NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc.(Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that the Company has been add…
NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc.(Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the appointment of William “B…
Reported positive interim results demonstrating durable responses in the ongoing Phase 2 ADVANCED-2 trial of TARA-002 in NMIBC Results from planned interim analysis of approximately 25 six-month evaluable BCG-Unresponsive patients expected…
NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara” or the “Company”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced…
TARA-002 demonstrates 100% complete response rate at any time and 67% 12-month landmark complete response rate in BCG-Unresponsive patients TARA-002 demonstrates 76% complete response rate at any time and 43% 12-month landmark complete res…
NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced it will host a conference c…
NEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc.(Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the appointment of Leonardo…
NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc.(Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that two presentations and a…